Case Studies

Rising to meet the key challenges our clients are facing

GLOBAL PATIENT CASE DEMAND STUDY

GLOBAL PATIENT CASE DEMAND STUDY

Global demand study for a rare type of hematological cancer with complex treatment dynamics

VIEW CASE STUDY
EARLY-STAGE DEMAND RESEARCH

EARLY-STAGE DEMAND RESEARCH

Global demand study for an early-stage oncology treatment in a high unmet need category

VIEW CASE STUDY
PIPELINE FORECAST

PIPELINE FORECAST

Global model for oncology condition with a complex patient flow

VIEW CASE STUDY
ON-MARKET PRODUCT FORECAST

ON-MARKET PRODUCT FORECAST

Forecasting with higher accuracy and greater versatility in a competitive market

VIEW CASE STUDY
GLOBAL LAUNCH FORECAST MODELING

GLOBAL LAUNCH FORECAST MODELING

Global launch forecast planning for an oncology asset

VIEW CASE STUDY
GROSS TO NET (GTN) MODELING

GROSS TO NET (GTN) MODELING

Designing a dynamic tool for detailed gross to net revenue modeling

VIEW CASE STUDY
LONG RANGE FORECAST PLANNING

LONG RANGE FORECAST PLANNING

Long range planning platform for portfolio assessment

VIEW CASE STUDY
STRATEGY AND PORTFOLIO OPTIMIZATION

STRATEGY AND PORTFOLIO OPTIMIZATION

Patient-level forecasting for four on-market products with $1B+ in total revenue

VIEW CASE STUDY
GO-TO-MARKET MODEL

GO-TO-MARKET MODEL

In-depth patient forecasting and tracking for a rare disease product

VIEW CASE STUDY
GLOBAL ONCOLOGY FORECASTING

GLOBAL ONCOLOGY FORECASTING

Building forecasting capabilities for a multi-national life science company

VIEW CASE STUDY
PAIN MANAGEMENT PORTFOLIO FORECAST

PAIN MANAGEMENT PORTFOLIO FORECAST

Designing a specialized forecast model for pain management portfolio

VIEW CASE STUDY
PAYERS AND THE INFLATION REDUCTION ACT

PAYERS AND THE INFLATION REDUCTION ACT

Initial Perspectives and Forecast Implications

VIEW WHITE PAPER
THE UPCOMING CROWDED PIPELINE CRISIS AND WHAT TO DO ABOUT IT

THE UPCOMING CROWDED PIPELINE CRISIS AND WHAT TO DO ABOUT IT

A Forecaster’s Perspective

VIEW WHITE PAPER
OPTIMIZING EARLY-STAGE COMMERCIAL ASSESSMENTS FOR EMERGING BIOPHARMA

OPTIMIZING EARLY-STAGE COMMERCIAL ASSESSMENTS FOR EMERGING BIOPHARMA

VIEW WHITE PAPER
captcha
protected by reCAPTCHA